Bernstein initiated coverage on Incyte with a new price target
$INCY
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Bernstein initiated coverage of Incyte with a rating of Mkt Perform and set a new price target of $99.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2026 | $99.00 | Mkt Perform | Bernstein |
| 3/16/2026 | $94.00 | Buy → Hold | Jefferies |
| 2/5/2026 | $135.00 | Buy | H.C. Wainwright |
| 1/20/2026 | $107.00 | Overweight → Equal Weight | Wells Fargo |
| 12/8/2025 | $121.00 | Neutral → Outperform | Mizuho |
| 11/3/2025 | $125.00 | Neutral → Buy | Guggenheim |
| 10/8/2025 | Outperform → Perform | Oppenheimer | |
| 8/6/2025 | $89.00 | Equal Weight → Overweight | Wells Fargo |
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy
Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
DEFA14A - INCYTE CORP (0000879169) (Filer)
SCHEDULE 13G/A - INCYTE CORP (0000879169) (Subject)
DEFA14A - INCYTE CORP (0000879169) (Filer)
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed across prespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes The frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide adde
Incyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is redefining what's possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Invest
The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train Genesis' next-generation GEMS AI platform as part of Incyte's efforts to speed up drug development across multiple programs Genesis to receive $120M with potential for success-based milestone payments and royalties Incyte (NASDAQ:INCY) and Genesis Molecular AI today announced a significant expansion of their strategic collaboration building and deploying state-of-the-art AI to accelerate the discovery of novel molecules for collaboration targets selected by Incyte. The expa
Bernstein initiated coverage of Incyte with a rating of Mkt Perform and set a new price target of $99.00
Jefferies downgraded Incyte from Buy to Hold and set a new price target of $94.00
H.C. Wainwright initiated coverage of Incyte with a rating of Buy and set a new price target of $135.00
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
Incyte (NASDAQ:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay will serve as a key member of the Executive Leadership Team and lead the Company's global finance organization responsible for Strategic Financial Planning; Capital Allocation; Investor Relations; Finance, Planning and Accounting; Global Sourcing; Environmental, Social, and Governance; Information Technology and Facilities. "Suky will oversee all aspects of our finance function. He will guide our capital allocation approach and apply effective financial stewardship in support of value creation for our sh
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther
Incyte (NASDAQ:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company's legal and compliance teams. "Richard joins us with a distinguished background, including many years of experience as a partner at a premier law firm, and a proven track record advising biopharma companies on corporate governance, strategic transactions, intellectual property and litigation," said Bill Meury, President and Chief Executive Officer, Incyte. "He possesses exceptional legal acumen and sound judgment to help
Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi® (ruxolitinib) net sales of $758 million, an increase of 7% compared to the same period in 2025 Opzelura® (ruxolitinib) cream net sales of $143 million and Hematology and Oncology portfolio net sales of $204 million, an increase of 20% and 116%, respectively, compared to the first quarter of 2025 Four anticipated approvals and launches from mid-2026 into early 2027 Advanced povorcitinib development program, including the New Drug Application (NDA) acceptance in hidradenitis suppurativa (HS) and positiv
Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q1 2026 Press Release: April 28, 2026 at 7:00 a.m. ET Q1 2026 Conference Call: April 28, 2026 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759527 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201
Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20% Y/Y) in the fourth quarter 2025 and $4.35 billion (+20%) for the full year 2025, exceeding full year 2025 net product revenue guidance of $4.23 - $4.32 billion Provides full year 2026 total net product revenue guidance range of $4.77 - $4.94 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance. "Our fourth quarter and full year 2025 result
SC 13G - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)